title: Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
abstract: We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.
authors.affiliation: Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: F V
authors.initials: FV
authors.lastname: Fossella
authors.forename: R J
authors.initials: RJ
authors.lastname: Winn
authors.forename: P Y
authors.initials: PY
authors.lastname: Holoye
authors.forename: B
authors.initials: B
authors.lastname: Hallinan
authors.forename: M N
authors.initials: MN
authors.lastname: Raber
authors.forename: K
authors.initials: K
authors.lastname: Hoelzer
authors.forename: J A
authors.initials: JA
authors.lastname: Young
authors.forename: J
authors.initials: J
authors.lastname: Readling
authors.forename: B
authors.initials: B
authors.lastname: Bowers
authors.forename: W K
authors.initials: WK
authors.lastname: Hong
mesh_terms: D000328:Adult; D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016597:Trimetrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D016597:Trimetrexate